Cytotoxic contamination in wards
Matthew Fowler, BScN, MSc, Heart of England NHS Foundation Trust, Birmingham, UK, discusses the issue of cytotoxic contamination for oncology…
Related Articles
DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis
Giuseppe Viale, MD, FRCPath, University of Milan, Milan, Italy, highlights key findings from the Phase II DESTINY-Breast12 trial (NCT04739761). The trial confirmed the efficacy of…
STELLAR: safety of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma
Markus Peck-Radosavljevic, MD, Medical University of Vienna, Vienna, Austria, discusses the hepatotoxicity and overall safety of lenvatinib versus sorafenib in patients with advanced or unresectable…
ERICA: olanzapine to manage T-DXd-related nausea & vomiting in patients with breast cancer
Hitomi Sakai, MD, Showa University, Shina-gawa-ku, Tokyo, presented findings from the Phase II ERICA trial (WJOG14320B) of olanzapine for preventing nausea and vomiting in patients…
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Evolving role of axillary surgery in breast cancer after neoadjuvant chemotherapy
Rosa Di Micco, MD, PhD, from San Raffaele Scientific and Research Hospital in Milan, Italy, discusses the evolving role of axillary surgery in breast cancer…
Choosing efficacious treatment options for hepatocellular carcinoma
Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses how the multitude of treatment options for hepatocellular carcinoma (HCC) blurs the line…
Enhancing surgical precision in breast cancer: the role of intraoperative ultrasound
Isabel Rubio, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the importance of innovation and education in breast cancer surgery at the ESSO 43…
PD-L1 expression concordance between primary and recurrent head and neck cancer
Luigi Lorini, MD, Humanitas Research Hospital, Rozzano, Italy, comments on the findings of the CONCORDL-1 study, which retrospectively analyzes PD-L1 expression concordance between primary and…
Importance of DNA repair pathway in therapeutic combination strategies
Naoto Ueno, MD, PhD, University of Hawai’i Cancer Center, Honolulu, HI, discusses recent preclinical findings from human samples indicating the potential role of DNA repair…
Emerging treatment strategies in EGFR-mutant NSCLC: osimertinib combinations and beyond
Nicolas Girard, MD, Institut Curie, Paris, France, discusses recent advancements in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), particularly first-line therapies involving osimertinib.…